Skip to main content

Resultats preliminaires d’injections intracaverneuses d’un donneur d’oxyde d’azote (NO), la linsidomine, dans le traitement de l’impuissance

Preliminary results with the nitric oxyde (NO) donor sin 1 in the treatment of human erectile dysfunction

Abstract

Recent experimental studies showed an important role of endothelium derived relaxing factor (EDRF) for cavernous smooth muscle relaxation. Since nitric oxide (NO) seems to account for the biological actions of EDRF, a study was done to examine a possible role of the NO-donor SIN-1 in the treatment of erectile dysfunction. To determine the therapeutic range, 0.1, 0.2, 0.5 and 1 mg SIN-1 were injected intracavernously in 2 patients with erectile dysfunction each. Then, 40 patients were injected 1 mg SIN-1 including 4 patients that had prolonged erections to minimal doses of papaverine-phentolamine and 4 patients that did not respond with a full erection to other pharmacologic agents. Intracavernous injection of SIN-1 induced a dose dependent erectile response by increasing the arterial inflow and relaxing cavernous smooth muscle. To 1 mg SIN-1, 19 patients had a full, 14 an almost full and 7 a moderate erection. There were no systemic or local side effects. In the patients with prolonged erections to papaverine-phentolamine, the mean duration of a full erection to SIN-1 was 68 minutes. Compared to a papaverine (15 mg/ml)-phentolamine (0.5 mg/ml) mixture, the erectile response to SIN-1 was superior in 8, comparable in 29 and inferior in 3 patients. Our preliminary data suggest a possible role of SIN-1 for the treatment of erectile dysfunction. The absence of prolonged erections by its spontaneous intracavernous decomposition, a maximal smooth muscle relaxation by a receptor independant action and its low cost indicate its potential to become a standard drug for intracavernous pharmacotherapy.

Resume

Des études récentes faites aussi bien in vitro que in vivo ont montré que le facteur relaxant d’origine endothéliale (EDRF) joue un rôle important dans l’érection. Dans la mesure où l’oxyde d’azote (NO) semble responsable des propriétés biologiques de l’EDRF, nous avons étudié l’effet d’une injection intracaverneuse d’un donneur de NO (Linsodomine ou SIN-1, CORSAVAL intracoronaireR). Pour préciser la dose thérapeutique, nous avons injecté de 0.1 à 1 mg chez 8 patients. Quarante patients, incluant 4 cas présentant des érections prolongées après dose faible de l’association Papavérine-Phentolamine, ont ensuite reçu 1 mg de SIN-1. L’injection a induit une réponse érectile dose-dépendante. Nous n’avons pas observé d’effets secondaires locaux ou systémiques. Chez les cas qui présentaient des érections prolongées avec d’autres drogues vaso-actives la durée moyenne d’érection fut de 68 mn. Nos résultats préliminaires suggèrent l’intérêt du SIN-1 pour le traitement de l’impuissance. Sa demi-vie courte, et sa destruction spontanée dans les corps caverneux, devraient éviter les érections prolongées. Le fait que son action ne soit pas dépendante d’un récepteur, ce qui devrait permettre une relaxation cavemeuse maximale, et son prix modéré font également du SIN-1 une altenative attractive

References

  1. 1

    -Aboseif S.R., Breza J., Diederichs W., Bosch R., Benard F. Stief C.G., Lue T.F., Tanagho E.A.: Effect of chronic intracavernous injection of papaverine and prostaglandin E 1 on erectile tissue in monkeys. J. Urol., 1988, 139: 257–259.

    Google Scholar 

  2. 2

    -de Groat W.C., Steers W.D.: Neuroanatomy and neurophysiology of penile erection. In Contemporary management of impotence and infertility, ed by Tanagho, E.A. Williams and Wilkins. Baltimore, 1988

    Google Scholar 

  3. 3

    -de Tejada S.I., Blanco R., Goldstein I, Azadzoi K., Morenas A. Krane R, Cohen R.A. Cholinergic neurotransmission in human corpus cavernosum. Am. J. Physiol. 1989, 254: 459–462.

    Google Scholar 

  4. 4

    -de Tejada I.S., Goldstein I., Azadzoi K., Krane R., Cohen R. Impaired new neurogenic and endothelium mediated relaxation of penile smooth muscle from diabetic men with impotence. New Engl. J. Med., 1989, 320: 1025–1027

    Article  Google Scholar 

  5. 5

    -Furchgott R.F.: Studies on endothelium dependant vasodilatation and the endothelium derived relaxing factor. Acta Physiol. Scand., 1990, 139: 257–265

    PubMed  Article  CAS  Google Scholar 

  6. 6

    -Furchtgott R.F., Zawadski J.V.: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond.), 1980: 288: 373–375

    Article  Google Scholar 

  7. 7

    -Holmquist F., Hedlund H., Andersson K.E. Characterisation of inhibitory neurotransmission in the isolated corpus cavernosum from rabbit and man. In: Holquist F. Nonadrenergic, noncholinergic mechanisms for contraction and relaxation of penile smooth muscle. Lund University Thesis 1991, pp 109–130

  8. 8

    -Holmquist F., Hellund H, Andersson K.E., L N-nitro arginine inhibits non-adrenergic, non cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol. Scand., 1991, 141: 441–442

    PubMed  Article  CAS  Google Scholar 

  9. 9

    -Holmquist F., Stief C.G., Jonas U., Andersson K.E. Effects of the nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand. sous presse.

  10. 10

    -Ignarro J.L. Biosynthesis and metabolism of endothelium-derived relaxing nitric oxide. Ann. Rev. Pharmacol. Toxicol. 1990, 30: 535–537

    Article  CAS  Google Scholar 

  11. 11

    -Jünemann K.P., Alken P., Pharmacotherapy of erectile dysfunction. Int. J. Impotence Res. 1989, 1: 71–94.

    Google Scholar 

  12. 12

    -Kim N., Azadzoi K.M., Goldstein I., de Tejada S.I.. A nitric oxide-like factor mediates non-adrenergic non-cholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J. Clin. Invest. 1991, 88: 112–113

    PubMed  Article  CAS  Google Scholar 

  13. 13

    -Lue T.F., Takamura T, Schmidt R.A., Tanagho E.A.: Hemodynamics of erection in the monkey. J. Urol. 1983, 130: 1237–1241

    PubMed  CAS  Google Scholar 

  14. 14

    -Reden J.: Molsidomine, Blood Vessels. 1990, 27: 282–294

    Article  CAS  Google Scholar 

  15. 15

    -Stief C.G., Djamilian M., Schaebsdau F., Truss M., Schlick R., Abicht J., Allhoff E.P., Jonas U. Single potential analysis of cavernous electric activity. World J. Urol., 1990, 8: 75–79

    Article  Google Scholar 

  16. 16

    -Stief C.G., Bähren W., Gall H, Scherb W. Functional evaluation of penile hemodynamics. J. Urol. 1988, 139: 734–737

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christian G. Stief.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stief, C.G., Holmquist, F. & Andersson, K.E. Resultats preliminaires d’injections intracaverneuses d’un donneur d’oxyde d’azote (NO), la linsidomine, dans le traitement de l’impuissance. Androl. 1, 83–84 (1991). https://doi.org/10.1007/BF03034179

Download citation

Key-words

  • erectile dysfunction
  • auto-injection therapy
  • EDRF
  • nitric oxyde Linsidomine

Mots-clés

  • Impuissance
  • auto-injections
  • EDRF
  • oxyde d’azote
  • Linsidomie